Latest California Healthline Stories
Many Doctors Treating Alcohol Problems Overlook Successful Drugs
Two prescription medications have been found to be successful in helping many patients with alcohol cravings. Yet they are rarely used and many patients don’t know they exist.
The Need To Replace EpiPens Regularly Adds To Concerns About Cost
The drug’s manufacturer says it has an expiration date of 12 to 18 months but that includes distribution time, so many customers find they have to buy a new device at least once a year.
Poll Finds Majority Of Americans Want Restraints On Drug Prices
As the spiraling costs attract headlines, many people are looking to the government to rein in prescription drug prices, according to the Kaiser Family Foundation poll.
Specialty Drug Costs Soar 30% For California Pension Fund
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
When Drug Reviewers Leave The FDA, They Often Work For Pharma
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
New California Law Allows Organizations to Buy EpiPens For Emergencies, But Will They?
The new law isn’t mandatory, and concerns about training and who can give life-saving shot remain.
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
Veterans Courted In California’s Ballot Fight Over Curbing Drug Prices
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
Candidates Decry High Drug Prices But Have Few Options For Voters
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.